Cg Oncology, Inc. (CGON) — 10-Q Filings

10-Q Filings (6)

• CG Oncology's Losses Mount Amid R&D Surge, Cash Dips to $45M — Nov 14, 2025 Risk: high
  CG Oncology, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $119.7 million, a substantial rise from $56
• CG Oncology's Losses Widen Amid Surging R&D for Bladder Cancer Drug — Aug 8, 2025 Risk: high
  CG Oncology, Inc. reported a net loss of $50.3 million for the three months ended June 30, 2025, a significant increase from the $34.7 million net loss for the
• CG Oncology Q1 2025 Update: R&D Expenses and Stock Plan Details — May 13, 2025 Risk: medium
  CG Oncology, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported research and development expenses for the first quarter
• CG Oncology Q3 10-Q: R&D Expenses and Stock Details — Nov 12, 2024 Risk: medium
  CG Oncology, Inc. filed its Q3 10-Q report on November 12, 2024, for the period ending September 30, 2024. The company reported research and development expense
• CG Oncology Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  CG Oncology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial position and results of operations. Key financial data
• CG Oncology, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: medium
  CG Oncology, Inc. (CGON) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. CG Oncology, Inc. filed a 10-Q report for the period ending March 31, 2024

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX